BBK II Trial design: Patients undergoing a two-stent approach for a de novo bifurcation lesion were randomized in a 1:1 fashion to either culotte stenting.

Slides:



Advertisements
Similar presentations
Www. Clinical trial results.org  Major Endpoints: Death, MI, stent thrombosis, TLR, TVR, MACE, and CKMB >3x nl  Major Endpoints: Death, MI, stent thrombosis,
Advertisements

BIFURCATION LESIONS Dr. Tahsin.N
For the Nordic-Baltic PCI Study Group
Richard Melsheimer Director, Medical Affairs Europe Centocor Eli Lilly and Company Coordinated Use of ReoPro and Drug Eluting Stents: Rationale and Evidence.
The REALITY Study Results. REALITY Study Design The REALITY Study : Prospective randomized clinical trial to evaluate the safety and efficacy of CYPHER®
Two-Year Outcomes After Everolimus- or Sirolimus- Eluting Stents in Patients With Coronary Artery Disease in the ISAR-TEST 4 Trial Robert A. Byrne, Adnan.
Rapamycin- and Paclitaxel-Eluting Stents With Identical Biodegradable Polymeric Coating and Design Trial Presented at The American College of Cardiology.
Two-Year Outcomes After Everolimus- or Sirolimus- Eluting Stents in Patients With Coronary Artery Disease in the ISAR-TEST 4 Trial Robert A. Byrne, Adnan.
A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.
Direct Stenting is Better (Debate Session) 동아의대 김 무 현.
Treatment of bifurcation lesions is a complex problem Different techniques are commonly used (Y-/T-stenting, „culotte“ technique, „kissing stent“ technique…)
ISAR-CABG Objective To compare the efficacy of DES with BMS in a randomized trial powered for clinical events Sample 610 patients with de novo SVG lesions.
1 Superiority Of A Simple Stenting Strategy For Coronary Bifurcation Lesions In The Drug-Eluting Stent Era: Evidence From A Meta-Analysis Of 1141 Patients.
Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.
Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Clinical restenosis after coronary stenting: perspectives.
(p for noninferiority = 0.01)
INFRATIBIAL INTERVENTIONS Current Results with DES
(DES)+BVS +DCB for long diffuse LAD disease
NORSTENT Trial design: Patients with obstructive coronary artery disease were randomized to a drug-eluting stent (DES) (n = 4,504) versus a bare-metal.
SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.
ABSORB Japan: 3-year Clinical and Angiographic Results of a Randomized trial Evaluating the Absorb Bioresorbable Vascular Scaffold vs. Metallic Drug-eluting.
LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.
TAXUS IV Trial Slow-rate release polymer-based paclitaxel-eluting stent compared with bare stent in patients with single de novo coronary lesions Presented.
DES Should be Used as the Default Stent in ACS!
Stenting of Coronary Arteries in Non Stress/Benestent Disease
(p < for group 1 or 2 vs. group 3)
TAXUS II and IV: two-year follow-up
AARDVARK Trial design: Patients with small abdominal aortic aneuryms (AAAs) were randomized in a 1:1:1 fashion to either perindopril 10 mg once daily,
Angiography-guided PCI
Primary endpoint at 1 year
MAGIC-AF Trial design: Patients with persistent atrial fibrillation (AF) and remaining in AF after pulmonary vein isolation alone were randomized to either.
MARFAN SARTAN Trial design: Marfan patients were randomized to losartan (n = 153) vs. placebo (n = 150). The dose of losartan was 50 mg for those
Losartan vs. Atenolol in Marfan Syndrome
Median total new lesion volume
Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.
FAIR Trial design: Patients with SFA in-stent restenosis (ISR) were randomized to either a paclitaxel-coated balloon (DCB) (dose 3.5 μg/mm2) or routine.
REALITY: 8 month results
ANTARCTIC Trial design: Patients with acute coronary syndrome undergoing stenting were randomized to tailored antiplatelet therapy (n = 435) versus conventional.
EXCITE ISR Trial design: Participants with femoropopliteal in-stent restenosis were randomized to excimer laser atherectomy + adjunctive angioplasty (n.
FAMOUS-NSTEMI Trial design: Participants with NSTEMI were randomized to an FFR-guided strategy (n = 176) vs. a coronary angiography-guided strategy (n.
TUXEDO–India Trial design: Patients with type 2 diabetes mellitus (DM2) and coronary artery disease undergoing PCI were randomized to receive Taxus Element.
ATMOSPHERE Trial design: Patients with symptomatic heart failure were randomized in a 1:1:1 fashion to either aliskiren 300 mg once daily, enalapril 5.
EVERBIO II Trial design: Patients with CAD were randomized in a 1:1:1 fashion to either Absorb BVS, Biomatrix Flex stent [BES], or Promus Element EES.
PROCAMIO Trial design: Patients with hemodynamically stable wide complex monomorphic tachycardia were randomized 1:1 to either intravenous procainamide.
BASKET-PROVE II Trial design: Subjects with stable or unstable coronary artery disease undergoing stent implantation were randomized to a biodegradable-polymer.
Presented at ACC 2003 Late Breaking Clinical Trials
BAT for HFrEF Trial design: Patients with chronic systolic HF were randomized in a 1:1 fashion to either baroreceptor activation therapy (BAT) or control.
NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.
ZEUS Trial design: Patients who were deemed uncertain DES candidates due to bleeding, thrombotic, or restenosis risk were randomized to receive either.
For the Nordic-Baltic PCI Study Group
Main branch restenosis at 1 year
RIDDLE-NSTEMI Trial design: Patients with NSTEMI were randomized to either immediate (within 2 hours) intervention or delayed (within 72 hours) intervention.
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
(p < 0.05 for paclitaxel angioplasty vs. either control)
(p < for noninferiority)
OSLER Trial design: Patients from five phase 2 trials and seven phase 3 trials with evolocumab were invited to participate in the OSLER extension program,
IMPRESSION Trial design: Patients presenting with acute MI and undergoing an invasive approach, along with ticagrelor loading dose, were randomized to.
(p = for noninferiority)
SMART-STRATEGY Trial design: Patients with a bifurcation coronary lesion were randomized to a conservative strategy (n = 128) vs. an aggressive strategy.
Presented at TCT 2006.
ITALIC Trial design: Patients with Xience V (everolimus-eluting stent) PCI were randomized in a 1:1 fashion to receive 6 or 24 months of dual antiplatelet.
DANAMI 3-DEFER Trial design: Patients presenting with STEMI and in whom the operators could establish TIMI 2-3 flow without stenting or those presenting.
Primary safety endpoint
Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial
MOMENTUM 3 Trial design: Patients with advanced heart failure were randomized to a centrifugal-flow pump (n = 152) vs. an axial-flow pump (n = 142). Results.
IVUS-XPL Trial design: Patients undergoing drug-eluting stent implantation for long coronary lesions were randomized to IVUS-guided PCI (n = 700) vs. angiography-guided.
American College of Cardiology Presented by Dr. Adnan Kastrati
The American College of Cardiology Presented by Dr. A. Abazid
NOBLE Trial design: Patients with unprotected left main disease were randomized to either PCI with a drug-eluting stent (DES) (88% biolimus) or CABG. They.
TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.
Presentation transcript:

BBK II Trial design: Patients undergoing a two-stent approach for a de novo bifurcation lesion were randomized in a 1:1 fashion to either culotte stenting or TAP stenting. They were followed for 12 months. Results (p = 0.038) Primary outcome, maximal in-stent % diameter stenosis at 9-month angiographic follow-up: Culotte vs. TAP stenting: 21% vs. 27%; p = 0.038 Binary restenosis (≥50%): 6.5% vs. 17%, p = 0.006; TLR at 12 months: 6.0% vs. 12.0%, p = 0.069 Stent thrombosis at 12 months: 0.7% vs. 0%, p = 0.32 % Conclusions When a two-stent bifurcation strategy is necessary, culotte is superior to TAP stenting for angiographic outcomes at 9 months This mirrors data from the NORDIC-II trial where culotte was superior to a crush technique, primarily due to a reduction in restenosis Primary outcome Culotte (n = 150) TAP (n = 150) Ferenc M, et al. Eur Heart J 2016;Aug 30:[Epub]